So in conclusion adoption of the M R C follow up follow up policy would have resulted in  targeting of cystoscopic follow up to higher risk group patients, a two percent increase in the cystoscopic resources required and delayed diagnosis of tumour progression in one patient, and as I've said I I think that G three P T one tumours should be excluded from  er  this type of protocol.